Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Deal Origination Executive Search For Sales Teams Corporate Development For Founders For Agencies For Investors Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Start Free
Allogene Therapeutics logo — A biotechnology company catalyzing cancer treatment through...

Allogene Therapeutics

A biotechnology company catalyzing cancer treatment through the development of CAR T therapy

Founded 2017 United States South San Francisco, United States 214 employees IPO Total: $1.05B Biotechnology

General Information

Company Name Allogene Therapeutics
Founded Year 2017
Location United States South San Francisco, United States +2
Employees 214
Industries Biotechnology
Funding Stage IPO
Social

Get notified when Allogene Therapeutics moves

Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.

Free · no account needed

AI Insight

Bounce Watch AI
2 months ago

Allogene Therapeutics has attracted significant investor confidence, raising over $310 million through two Post-IPO Equity rounds in May 2024 and April 2026. This substantial capital infusion is set to accelerate their clinical development pipeline, as evidenced by their upcoming discussion of the ALPHA3 trial at the Full Endpoints News R&D 15 Session in June 2026.

Signal Types
Funding Clinical Development Event Participation
Strategic Labels
Capital Infusion Clinical Advancement Industry Engagement
Next Move: Development
·
Impact: 8/10
·
Ideal For: Biotechnology Growth Equity — Clinical Stage

About Allogene Therapeutics

Allogene Therapeutics, based in South San Francisco, is a clinical-stage biotechnology company spearheading the evolution of cancer treatment with its innovative AlloCAR T products. Founded in 2017, the company is at the forefront of developing allogeneic chimeric antigen receptor T cell therapies, targeting both cancer and autoimmune diseases.

The company leverages its expertise to catalyze the future of immunotherapy by eliminating constraints posed by traditional autologous CAR T therapies, such as individualized production and lengthy wait times. This pioneering approach positions Allogene Therapeutics as a decisive player in the biotechnology landscape.

Allogene Therapeutics recently secured a significant $110M in Post Ipo Equity investment as of May 2024, underscoring continuous investor confidence in its visionary endeavors. As the company advances its pipeline, it remains a promising candidate for partnerships and further investment opportunities.

Taxonomy: clinical-stage, cancer treatment, immunotherapy, CAR T therapy, AlloCAR T products, allogeneic therapies, oncology, autoimmune disease, cell therapy, therapy development, biopharmaceuticals, medical innovation, South San Francisco

Services & Products

Development of CAR T cell products
Clinical trial management
Gene editing and engineering
Manufacturing of allogeneic therapies
Therapeutic innovation for cancer and autoimmune diseases

Target Customers

Patients with blood cancers Patients with solid tumors Patients with autoimmune diseases Healthcare providers Biopharmaceutical partners

Funding Rounds & Investors (4)

View All
Funding Stage Amount Investors Lead Investors Date
Post Ipo Equity •••••• - 01 Apr 2026
Post Ipo Equity •••••• - 01 May 2024
Series A •••••• - 01 Oct 2018
Series A •••••• 4
Investor Investor
•••• •••• 		01 Apr 2018

Allogene Therapeutics Alternatives & Competitors

Allogene Therapeutics vs
Sarepta Therapeutics
Sarepta Therapeutics United States

Dragging Tomorrow Into Today.

IPO
1154 employees
Compare Allogene Therapeutics vs Sarepta Therapeutics
Allogene Therapeutics vs
Agenus
Agenus United States

Agenus is a leading immuno-oncology company targeting cancer and infectious diseases with a comprehe...

Post Ipo Debt
291 employees
Biotechnology, Health and Wellness
Compare Allogene Therapeutics vs Agenus
Allogene Therapeutics vs
Akebia Therapeutics
Akebia Therapeutics United States

We're focused on the development & commercialization of therapeutics for people living with kidney d...

Post Ipo Debt
268 employees
Biotechnology, Health Care
Compare Allogene Therapeutics vs Akebia Therapeutics
Also compare with: Allogene Therapeutics vs Eiger BioPharmaceuticals Eiger BioPharmaceuticals

FAQ About Allogene Therapeutics

A biotechnology company catalyzing cancer treatment through the development of CAR T therapy
Allogene Therapeutics was founded in 2017.
Allogene Therapeutics is headquartered in South San Francisco, United States.
Allogene Therapeutics operates in the following industries: Biotechnology.
Allogene Therapeutics has approximately 214 employees.
Allogene Therapeutics has completed 4 funding rounds, raising a total of $1.05B. The latest funding stage is IPO.
Allogene Therapeutics offers: Development of CAR T cell products, Clinical trial management, Gene editing and engineering, Manufacturing of allogeneic therapies, Therapeutic innovation for cancer and autoimmune diseases.
Top alternatives and competitors to Allogene Therapeutics include Sarepta Therapeutics, Agenus, Akebia Therapeutics, Forma Therapeutics, ITM Isotope Technologies Munich SE. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Allogene Therapeutics and Sarepta Therapeutics are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Don't just browse. Track.

Signal Tracker monitors Allogene Therapeutics and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.

Start Tracking — Free

One analytics cookie (Google Analytics). Cookie Policy